WuXi AppTec reported first-half 2026 revenue of RMB 28.897 billion, up 38.93% year on year, and net profit attributable to shareholders of RMB 11.08 billion, up 29.43%, surpassing RMB 10 billion for the first time in a half-year period. The company raised its full-year 2026 guidance, lifting adjusted free cash flow to RMB 13.5-14.5 billion. It also proposed a dividend of RMB 5.10 per 10 shares and disclosed ongoing litigation against the US Department of Defense over its 1260H list designation.
Jitai Technology announced on the Hong Kong Stock Exchange that its self-developed AiTEM artificial intelligence formulation innovation platform will be locally deployed at Jiangsu Hengrui Medicine Co. , Ltd. The deployment is intended to accelerate the efficiency of drug formulation development. The collaboration centres on the AI formulation platform field, with the aim of enhancing the automation and intelligence level of the pharmaceutical research and development process through technology deployment.